The latest price target for Steris (NYSE:STE) was reported by Morgan Stanley on August 8, 2025. The analyst firm set a price target for $295.00 expecting STE to rise to within 12 months (a possible 16.93% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Steris (NYSE:STE) was provided by Morgan Stanley, and Steris maintained their overweight rating.

The last upgrade for Steris PLC happened on July 15, 2025 when Morgan Stanley raised their price target to $276. Morgan Stanley previously had an equal-weight for Steris PLC.

The last downgrade for Steris PLC happened on April 14, 2023 when Piper Sandler changed their price target from $215 to $197 for Steris PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Steris, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Steris was filed on August 8, 2025 so you should expect the next rating to be made available sometime around August 8, 2026.

While ratings are subjective and will change, the latest Steris (STE) rating was a maintained with a price target of $276.00 to $295.00. The current price Steris (STE) is trading at is $252.29, which is out of the analyst’s predicted range.